Ucb Pharma Gmbh

Jens Riedner

Hans-Michael Wolff

Luc Quere

Gavin Dunne

The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (II) in a single step reaction.

Synthesis scheme for lacosamide

The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X-ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01&#xb1;0.2 (&#xb0;2&#x3b8;), measured with a Cu&#x2014;Kirradiation (1.54060), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.

Polymorphic form of rotigotine and process for production

The present invention relates to a novel polymorphic form of rotigotine characterized by at least one of the following powder X-ray diffraction peaks: 12.04, 13.68, 17.72 and 19.01&#xb1;0.2 (&#xb0; 2&#x3b8;), measured with a Cu&#x2014;Kirradiation (1.54060 &#x212b;), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's disease and other dopamine-related disorders.

The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the O-methylation of a compound of formula I to produce a compound of formula II in a single step reaction.

Growing community of inventors

Ennis, Ireland

Jens Riedner